Aktis Oncology (AKTS)
Develops targeted radiopharmaceuticals for solid tumors using miniprotein radioconjugates.
$21.04
vs last close−1.07 (−4.84%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 64.30% | 34.34M shares | |
|---|---|---|---|
| 116 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Strategic holders | 11.88% | 6.34M shares | |
| 1 holder · as of Jan 15, 2026 | |||
| Other | ≈ 23.82% | 12.72M shares | |
| remainder | |||
53.40M company shares as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
116 holders · 34.34M shares · 55 new positions · 83 increased · 17 reduced · 8 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Bioimpact Capital LLC | 4.84M | 9.06% | 0 | Aug 14, 2026 |
| Ecor1 Capital, LLC | 4.82M | 9.03% | 0 | Aug 14, 2026 |
| Blue Owl Capital Holdings LP | 3.07M | 5.75% | −91.1K | Aug 11, 2026 |
| BlackRock, Inc. | 2.28M | 4.27% | +166.2K | Aug 7, 2026 |
| T. Rowe Price Investment Management, Inc. | 2.05M | 3.84% | −72.4K | Aug 14, 2026 |
| Wellington Management Group LLP | 1.97M | 3.68% | −350.8K | Aug 14, 2026 |
| RTW Investments, LP | 1.59M | 2.98% | 0 | Aug 14, 2026 |
| Ra Capital Management, L.P. | 1.31M | 2.46% | −188.7K | Aug 14, 2026 |
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
Nothing filed in the last 12 months.
House and Senate disclosures
Not reported.